Technology
Health
Pharmaceutical
BiondVax Pharmaceuticals
$6.609876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$6.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.07 (1.06%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell BVXV and other stocks, options, ETFs, and crypto commission-free!
About
BiondVax Pharmaceuticals Ltd. American Depositary Shares, also called BiondVax Pharmaceuticals, is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. Read More It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.
Employees
21
Headquarters
Jerusalem, Jerusalem
Founded
2003
Market Cap
43.13M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
5.90K
High Today
$6.69
Low Today
$6.54
Open Price
$6.55
Volume
1.80K
52 Week High
$7.26
52 Week Low
$3.51
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2015 IPO
Asia (Non-China)
Asia
News
Yahoo FinanceMay 13
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
JERUSALEM, Israel, May 13, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel. BiondVax Pharmaceuticals Logo (PRNewsfoto/Biondvax Pharmaceuticals Ltd) More Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical effic...
Yahoo FinanceApr 30
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
JERUSALEM, April 30, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate currently undergoing a pivotal clinical efficacy Phase 3 trial, today announced its fourth quarter and full year financial results for the year ended December 31, 2018 and provided a business update. BiondVax Pharmaceuticals Logo (PRNewsfoto/Biondvax Pharmaceuticals Ltd) More Fourth Quarter 2018 Financial Summary Res...
Price Paid on Robinhood
2% Higher
Right Now
52 Week Low
$3.51
Average Price Paid
$6.47
52 Week High
$7.26
Earnings
-$0.05
-$0.03
-$0.02
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
-$0.05 per share